Skip to main content
Publications
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M Secukinumab provides better relief from psoriasis impact on personal relationships than etanercept
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo
Balp M, Abuzakouk M, Berard F, Canonica GW, Gimenez-Arnau A, Hollis K Comparison of direct healthcare costs associated with chronic spontaneous/idiopathic urticaria in 7 countries - results from the ASSURE-CSU study
Hollis K Assessing health-utility values for chronic spontaneous/idiopathic urticaria in real-world using the EQ-5D: results from ASSURE-CSU study
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo
Zheng S, D'Souza VK Lipoxin A4 promotes lung epithelial repair whilst inhibiting fibroblast proliferation 10.1183/23120541.00079-2015
Taylor S, Demeyin (Nuabor) W Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project 10.1136/bmjopen-2016-011773
Mease P, Schwab PE Treatment patterns, health care resource utilization, and costs associated with psoriatic arthritis among Humana commercial and Medicare member populations
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo
Gottlieb AB, Pariser D, Tsai TF, Pinter A, Zhou Y, Gilloteau I, Mordin M Davenport E Secukinumab provides greater 52-week sustained relief in dermatology-specific quality-of-life impact than ustekinumab
Puig L, Sofen H, Augustin M, Abramovits W, Kingo K, Gilloteau I, Zhao Y, Mordin M Secukinumab provides greater 52-week improvements in patient-reported outcomes versus ustekinumab in patients with moderate to severe psoriasis
Zografos LJ Wolin DL Calingaer B Davenport EK Hollis KA Evaluating physician knowledge of risks and safe use of Xarelto (rivaroxaban)
Lebwohl M, Blauvelt A, Augustin M, Zhao Y, Gilloteau I, Herrera V, Milutinovic M, You R, Mordin M McLeod L Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo 10.1016/j.jaad.2016.02.1049
Bartis D, Crowley LE, D'Souza VK Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis 10.1186/s12890-016-0211-7
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M Odom D Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept
White MV, Silvia S, Hollis K Goss D Odom D Bartsch J EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events
